Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (GEP-NET)

1 total trials

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Showing 1–1 of 1 trials